- Home
- DXCM
DXCM
DexCom Inc.
as 03-28-2025 4:00pm EST
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 35.7B | IPO Year: | 2005 |
| Target Price: | $99.82 | AVG Volume (30 days): | 4.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 17 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.42 | EPS Growth: | 9.35 |
| 52 Week Low/High: | $62.34 - $141.99 | Next Earning Date: | 04-24-2025 |
| Revenue: | $4,033,000,000 | Revenue Growth: | 11.34% |
| Revenue Growth (this year): | 16.49% | Revenue Growth (next year): | 15.58% |
Stock Insider Trading Activity of DexCom Inc. (DXCM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Brown Michael Jon | DXCM | EVP, Chief Legal Officer | Mar 12 '25 | Sell | $70.38 | 13,000 | $914,941.30 | 105,602 | |
| SAYER KEVIN R | DXCM | Chairman, CEO & President | Mar 12 '25 | Sell | $70.38 | 32,498 | $2,287,212.49 | 372,029 | |
| Leach Jacob Steven | DXCM | EVP, Chief Operating Officer | Mar 12 '25 | Sell | $70.38 | 14,076 | $990,670.29 | 313,497 | |
| Sylvain Jereme M | DXCM | EVP, Chief Financal Officer | Mar 8 '25 | Sell | $73.99 | 7,000 | $516,830.28 | 139,812 | |
| Sylvain Jereme M | DXCM | EVP, Chief Financal Officer | Jan 28 '25 | Sell | $86.91 | 2,090 | $181,650.47 | 139,812 | |
| SAYER KEVIN R | DXCM | Chairman, CEO & President | Jan 28 '25 | Sell | $86.91 | 33,359 | $2,899,367.46 | 372,029 | |
| Dolan Matthew Vincent | DXCM | EVP, Strategy & Corporate Dev | Jan 28 '25 | Sell | $86.91 | 1,183 | $102,819.74 | 42,044 | |
| Leach Jacob Steven | DXCM | EVP, Chief Operating Officer | Jan 28 '25 | Sell | $86.91 | 2,634 | $228,932.00 | 313,497 | |
| Stern Sadie | DXCM | EVP, Chief HR Officer | Jan 28 '25 | Sell | $86.91 | 2,093 | $181,911.21 | 74,261 |
Latest DexCom Inc. News
DXCM Breaking Stock News: Dive into DXCM Ticker-Specific Updates for Smart Investing
MedTech Dive
2 days ago
Dexcom rejects claims of unauthorized device changes in FDA warning letter
Zacks
2 days ago
DXCM Stock Falls as FDA Warnings Raise Concern for 15-Day G7 Approval
Simply Wall St.
3 days ago
DexCom (NasdaqGS:DXCM) Expands Wearable Integration and Appoints New Chief Commercial Officer
MedTech Dive
3 days ago
Dexcom’s FDA warning letter reveals unauthorized changes to sensors
Zacks
3 days ago
DXCM Stock Gains Following New Data on Upcoming G7 CGM Sensor
Argus Research
4 days ago
DXCM: Raising target price to $77.00
Argus Research
4 days ago
DXCM: Raising target price to $40.00
MT Newswires
4 days ago
DexCom Names Jon Coleman as Chief Commercial Officer
Compare DXCM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DXCM DexCom Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.